Alnylam (ALNY) Soars 3.6%: Is Further Upside Left in the Stock?

12:34pm, Friday, 14'th Oct 2022 Zacks Investment Research
Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Where Alnylam Pharmaceuticals Stands With Analysts

02:06pm, Thursday, 13'th Oct 2022 Benzinga
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 6 0
Deutsche Bank cut Deere & Company (NYSE: DE) price target from $389 to $365. Deere shares rose 0.5% to $363.00 in pre-market trading. BTIG cut Roblox Corporation (NYSE: RBLX) price target from $58

3 Top Biotech Stocks Defying the Bear Market

09:52am, Tuesday, 11'th Oct 2022 The Motley Fool
Bear market, shmear market. These biotech stocks are soaring despite the market downturn.

Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion

04:12pm, Friday, 07'th Oct 2022 Zacks Investment Research
The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.
The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.

Where Alnylam Pharmaceuticals Stands With Analysts

09:02pm, Monday, 03'rd Oct 2022 Benzinga
Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with unders
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 7 0 0

Analyst Ratings for Alnylam Pharmaceuticals

05:14pm, Monday, 03'rd Oct 2022 Benzinga
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 7 0 0

Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More

04:17pm, Thursday, 22'nd Sep 2022 Zacks Investment Research
Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.

Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod

10:32pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
RBC Capital Markets raised the price target on Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) from $225 to $250. The analyst says that the company is confident that the recent APOLLO-B validates the t
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 9th annual series of “RNAi Roundtabl
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE